SAN CARLOS, Calif.
NuGEN Technologies, Inc. today announced the appointment of Nitin Sood as Chief Executive Officer. He succeeds Elizabeth Hutt who recently left to pursue another opportunity.
Mr. Sood comes to NuGEN from PerkinElmer, where he served as Vice President and General Manager of their life science instruments business spanning a portfolio of products in imaging, detection, tissue pathology, automation and NGS sample prep. Prior to his current role, Mr. Sood was the Chief Executive Officer of Boreal Genomics, a developer of “liquid biopsy” tools for non-invasive detection of tumor mutation profiles. Prior to that, Mr. Sood served as General Manager of the Automation and Electrophoresis business units at Agilent Technologies, where he commercialized several successful products in the sample prep markets. He holds master’s degrees in both computer science and molecular biology.
“Nitin’s track record of success, technical expertise, and extensive experience in product commercialization made him the ideal person to lead NuGEN through its next phase of growth and innovation,” said Jeff Bird, Chairman of NuGEN’s Board of Directors and a Managing Director at Sutter Hill Ventures.
“NuGEN’s differentiated technology, extensive customer base and innovative pipeline of new products makes this an exciting opportunity for me,” said Mr. Sood. “I look forward to working with the entire NuGEN team to serve our customers and support their breakthroughs in both research and diagnostic applications of genomics.”
NuGEN’s products offer rapid and simple workflows for a broad range of next generation DNA and RNA sequencing applications, enabling highly sensitive detection of variants and expression levels from tissues, single cells and liquid biopsies. NuGEN’s products are used by thousands of scientists worldwide and have been cited in over 2,000 peer-reviewed publications.
About NuGEN Technologies, Inc.
Based in San Carlos, CA, NuGEN Technologies, Inc., provides innovative products used to prepare biologic samples for targeted genomic analysis. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries. NuGEN has a long history of launching products with market leading specs, including the recent launch of the Ovation SoLo RNA- Seq System that enables targeted depletion of unwanted transcripts and library construction from single cells, and the Ovation Fusion Panel Target Enrichment System that enables detection of gene fusions across 502 cancer genes. To learn more about NuGEN visit www.nugen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160614005448/en/
CONTACT
NuGEN Technologies, Inc.
Carol Short, 650-590-3002
media@nugen.com
